

Special Issue

Polymeric Nanoplatfoms for Immunotherapy and Diagnosis

Message from the Guest Editors

Immunotherapy targeting the host immune system has revolutionized oncology. However, due to uncontrolled accumulation in tissues and the ever-present bioactivity of immunotherapeutics, most patients suffer from the risk of immune-related adverse events (IRAEs). With the advantages of controllability of delivery and modular flexibility, polymeric nanoplatfoms offer the opportunity to bring immunotherapies into clinical use in a safe and effective manner. In addition, patients with many non-immunogenic “cold” tumors show low response rates to immunotherapies, so real-time tracking of the immune microenvironment of tumors is also essential for the efficacy of immunotherapies. To promote the development in the field of immunotherapy, the introduction of new polymeric nanoplatfoms for immunotherapy and diagnosis is of great significance. The proposed topics will primarily focus on the demonstration of novel polymeric materials and provide a general picture of the suitability of a particular material for immunotherapy and diagnosis. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. Shasha He

Prof. Dr. Jingchao Li

Prof. Dr. Dongfang Zhou

Deadline for manuscript submissions

closed (30 April 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/189409

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).